Qingyuan Kaiwu Completes Pre-A Round Financing, Files Prospectus to Lead China's $100B Laboratory Automation Market
After securing two rounds of funding totaling tens of millions of yuan from prominent industry funds, including Shuimu Ventures and the Changfazhan Zhiheng Direct Investment Fund,Beijing Qingyuan Kaiwu Technology Co., Ltd. (hereinafter referred to as “Qingyuan Kaiwu”)Furthermore, it was recently announced that the completion ofBeijing Yuanhui Venture Capital Management Co., Ltd. (hereinafter referred to as "Yuanhui Chuangyi")Exclusively InvestedTens of Millions in Pre-A RoundFinancing. The funds from this round will be used forTechnical breakthroughs, core module R&D, clinical trial applications, and production base construction for the product。
Qingyuan Kaiwu was established on October 28, 2021, with its R&D base located in the Life Science Park in Changping District. The companyMulti-Dimensional Liquid Control Systemas the core, buildFlexible Modular Technology System, we are implementing a two-pronged product strategy: automated and intelligent laboratory equipment, and high-end life science instrumentation. Focusing on industrial application scenarios such as sequencing, mass spectrometry, synthetic biology, and drug R&D, we provide highly customized, integrated, automated, and intelligent solutions for biological sample pre-processing to support life science services, biopharmaceutical R&D, clinical diagnostic applications, and the synthetic biology industry.
Amid the overarching trend of domestic substitution and the continuous innovation and transformation of science and technology, market demand for automated and intelligent laboratory solutions is growing steadily. Laboratory automation has become a focal technology attracting significant attention from research institutions, industrial sectors, and the testing and inspection industry. Seizing this momentum, Qingyuan Kaiwu has focused on overcoming challenges in core technologies and key modules, achieving comprehensive product deployment in pre-sequencing processing. Its offerings primarily include nucleic acid pre-processing workstations, sample preparation systems, nucleic acid fragmentation equipment, sequencing library preparation workstations, nucleic acid concentration quality control instruments, and related consumables. In the field of mass spectrometry pre-processing, the company provides small-molecule extraction workstations tailored for the detection of genetic metabolites, vitamins, drug concentrations for psychiatric disorders, and pathogenic microorganisms; pre-processing workstations for nucleic acid library construction and protein/peptide extraction; and integrated nucleic acid mass spectrometry systems. In synthetic biology, addressing the critical pain points and challenges of large-scale industrial users, Qingyuan Kaiwu offers long-fragment gene assembly systems, magnetic bead-based large-volume plasmid extraction workstations, and highly sensitive online Raman spectroscopy detection systems (used for intracellular yield evaluation).Three products have been launched, with annual sales exceeding ten million yuan.
At the 7th “Maker China” SME Innovation and Entrepreneurship Competition, jointly organized by the Ministry of Industry and Information Technology (MIIT) and the Ministry of Finance, Qingyuan Kaiwu stood out among competitors to rank among the top 500 nationwide and placed within the top four in the Beijing region for the corporate category of the Biomedical Pharmaceutical thematic competition. Furthermore, at the 7th “Maker China” Biomedical SME Innovation and Entrepreneurship Competition, hosted by MIIT and the Beijing Municipal Bureau of Economy and Information Technology, the company won the Second Prize in the corporate category.
Honing Core Competencies, Continuously Winning Prestigious Industry Awards
For this financing round,Wang Dong, Founder of Qingyuan Kaiwu“He stated, ‘Amid the pressures of an economic downturn, securing support from Yuanhui Chuangyi has afforded us more time and confidence to devote ourselves to research and development. Mr. Zhang Fan, Founder and Managing Partner of Yuanhui Chuangyi, earned both his bachelor’s and master’s degrees from Tsinghua University and brings extensive management experience, which constitutes a valuable asset for Qingyuan Kaiwu.’”
Mr. Zhang Fan, Yuanhui ChuangyiHe stated, “Wang Dong, founder of Qingyuan Kaiwu, has been deeply engaged in the life sciences instrumentation and molecular diagnostics markets for nearly two decades. The core members of its founding team possess comprehensive backgrounds in the R&D and market operations of automated detection equipment, including sequencing, mass spectrometry, and flow cytometry, along with experience in innovative product development and commercialization. Furthermore, they demonstrate a clear understanding of corporate social responsibility and embrace the principle of ‘business for good.’ They are committed to leveraging technology to benefit humanity while harnessing the wealth-creating power of business to sustainably support philanthropic initiatives.”
About Yuanhui Chuangyi
Yuanhui Chuangyi, established in 2010, has long been committed to exploring innovative models that integrate venture capital with philanthropy. From a long-term perspective, it seeks out and partners with passionate entrepreneurs and growth-stage enterprises possessing hard-core technologies, fostering their mutual development. Guided by the core principles of “Business for Good” and “Technology for the Benefit of Humanity,” it influences companies to continuously refine their social value systems. Through its “Philanthropic Investment” model—combining venture capital, grant-making foundations, and modern grassroots philanthropy—it enables business to sustainably fuel and empower modern charitable initiatives, while helping enterprises enhance their sustainable development capabilities.
Recommended Reading: